Expectedly, the pre-treatment by celecoxib decreased the expression of MDR-1 and elevated the cellular PpIX levels induced by 5-ALA, resulting in the enhanced anti-tumor effects of the combination therapy in the GSC-bearing glioma model. This evidence concerns the gene ABCB1 and neoplasm.